Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Jann

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Clinical Pharmacy|December 1, 1987
Treatment of panic and phobic disordersM W Jann, N M Kurtz
Clinical Pharmacy|November 1, 1992
Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitorsS R Grimsley, M W Jann
Clinical Pharmacokinetics|June 1, 1995
Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugsG V Milton, M W Jann
Psychosomatics|July 1, 1982
Respiratory dyskinesiaM W Jann, A H Bitar
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 10, 2000
Major depression in women: a review of the literatureH D Desai, M W Jann
CNS Drugs|August 29, 2001
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspectiveH D Desai, J Seabolt, M W Jann
Drugs & Aging|April 8, 2000
Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderlyC M VanDenBerg, Y Kazmi, M W Jann
Neurology|October 1, 1987
Transitional polytherapy, liver enzymes, and valproic acid hepatotoxicityG S Fidone, M W Jann, S Rosenthal
Drug Intelligence & Clinical Pharmacy|January 1, 1984
Carbamazepine for patients with affective target symptomsM W Jann, S R Saklad, L Ereshefsky
Pediatrics|November 1, 1986
Interaction of dietary pudding with phenytoinM W Jann, J Bean, G S Fidone
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Clinical Pharmacy|December 1, 1987
Treatment of panic and phobic disordersM W Jann, N M Kurtz
Clinical Pharmacy|November 1, 1992
Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitorsS R Grimsley, M W Jann
Clinical Pharmacokinetics|June 1, 1995
Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugsG V Milton, M W Jann
Psychosomatics|July 1, 1982
Respiratory dyskinesiaM W Jann, A H Bitar
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|August 10, 2000
Major depression in women: a review of the literatureH D Desai, M W Jann
CNS Drugs|August 29, 2001
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspectiveH D Desai, J Seabolt, M W Jann
Drugs & Aging|April 8, 2000
Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderlyC M VanDenBerg, Y Kazmi, M W Jann
Neurology|October 1, 1987
Transitional polytherapy, liver enzymes, and valproic acid hepatotoxicityG S Fidone, M W Jann, S Rosenthal
Drug Intelligence & Clinical Pharmacy|January 1, 1984
Carbamazepine for patients with affective target symptomsM W Jann, S R Saklad, L Ereshefsky
Pediatrics|November 1, 1986
Interaction of dietary pudding with phenytoinM W Jann, J Bean, G S Fidone
Pageof 10